Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2005 by Hadassah Medical Organization.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Beth Israel Deaconess Medical Center
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00262093
First received: December 4, 2005
Last updated: March 19, 2007
Last verified: November 2005

December 4, 2005
March 19, 2007
November 2005
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00262093 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence

The reason for having a higher incidence of preeclampsia in primiparas may involve angiogenesis imbalance in these patients.

Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.

We intend to check the angiogenesis profile of primiparas as compared to multiparas.

Observational
Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Not Provided
Not Provided
Pre-Eclampsia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
Not Provided

Inclusion Criteria:

  • Every delivery

Exclusion Criteria:

  • Preeclampsia or pregnancy induced hypertension
Female
Not Provided
Yes
Contact: Yuval Bdolah, MD, MSc 972-2-5844111 ybdolah@hadassah.org.il
Contact: Hadas Lemberg, PhD 972-2-6777572 lhadas@hadassah.org.il
Israel
 
NCT00262093
PRIMIMULTI-HMO-CTIL
Not Provided
Not Provided
Hadassah Medical Organization
Beth Israel Deaconess Medical Center
Principal Investigator: Yuval Bdolah, MD, MSc Hadassah-Hebrew University Medical School
Hadassah Medical Organization
November 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP